Sarepta Pharmaceuticals Inc (NASDAQ: SRPT) stock is plummeting down, down 31.4% at $16.77 at last glance. Though the biotech ...

Zoetis Inc (NYSE:ZTS) shares are at the bottom of the SPX today, down 12.5% to trade at $126.32 at last glance, after the company cut its 2025 outlook due to growth concerns. The equity is brushing ...

Calls have been popular. At the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), PLTR sports a 10-day put/call volume ratio of 1.66 that ranks in the ...

Despite the pullback, UBER is still near record high territory, within striking distance of its September peak of $101.99. Uber Technologies stock has added 50% since January, and ahead of today's ...

Despite the pullback, UBER is still near record high territory, within striking distance of its September peak of $101.99. Uber Technologies stock has added 50% since January, and ahead of today's ...

The shares of Uber Technologies Inc (NYSE:UBER) are off 7.7% ahead of the bell, brushing off a third-quarter revenue win after the company lowered its fourth-quarter profit outlook. Despite the ...

The Dow fell 226 points today, while the tech-heavy Nasdaq rose thanks to outsized moves from Big Tech and AI stocks ...

Analysts have yet to make any adjustments on CIFR today, though the stock saw a slew of price-target hikes last month. Of the ...

Though short interest is down 18.8% in the past two reporting periods, it still accounts for 5% of the stock's total available float. At the stock's average pace of trading, it would take short ...

At last check, IREN was up 19% to trade at $72.27, on track for its biggest single-session gain in nearly a year. The stock ...

And tech heavyweights reported earnings, with little net impact on the S&P 500 Index (SPX -- 6,840.20). Meta Platforms (META) and Microsoft (MSFT) experienced significant negative reactions, but those ...

Biotech stock Alvotech SA (NASDAQ:ALVO) is plummeting to three-year lows, down 29.9% at $5.36 at last check. The FDA declined to approve the company's arthritis drug, sending a list of deficiencies ...